Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Treatment Phase	STARTED	Placebo	57
Treatment Phase	STARTED	Galcanezumab 300mg	52
Treatment Phase	Received at Least One Dose of Study Drug	Placebo	57
Treatment Phase	Received at Least One Dose of Study Drug	Galcanezumab 300mg	49
Treatment Phase	COMPLETED	Placebo	45
Treatment Phase	COMPLETED	Galcanezumab 300mg	45
Treatment Phase	NOT COMPLETED	Placebo	12
Treatment Phase	NOT COMPLETED	Galcanezumab 300mg	7
Post Treatment Follow-up Phase	STARTED	Placebo	50
Post Treatment Follow-up Phase	STARTED	Galcanezumab 300mg	47
Post Treatment Follow-up Phase	COMPLETED	Placebo	47
Post Treatment Follow-up Phase	COMPLETED	Galcanezumab 300mg	45
Post Treatment Follow-up Phase	NOT COMPLETED	Placebo	3
Post Treatment Follow-up Phase	NOT COMPLETED	Galcanezumab 300mg	2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02397473/flow